Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry
Nephrology · 2024
DOI: 10.1111/nep.14366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, 2024. Verfasst von Yuka Sugawara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Endocrinology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Registries, Renal Dialysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Aim
The effectiveness of the coronavirus disease (COVID‐19) vaccine in Japanese patients undergoing haemodialysis has previously not been evaluated on a large scale. We analyzed data from the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR), covering nearly all Japanese patients undergoing dialysis (~95% coverage), to examine the association between COVID‐19 vaccination and infection or mortality.
Methods
We used data from the JRDR end‐of‐year surveys conducted in 2020 and 2021, including information on the COVID‐19 vaccination and infection months. COVID‐19 infection incidence and its associated mortality rates based on vaccination status (time updated) and odds ratio (OR) (vaccinated vs. unvaccinated) were estimated monthly from April 2021, when vaccination commenced in Japan.
Results
COVID‐19 infection analysis included 228 865 patients (215 941 vaccinated and 12 924 unvaccinated patients at the end of 2021). The age‐ and sex‐adjusted ORs (aORs) were significantly lower in August, September, October and November 2021, especially in September (aOR [95% confidence interval (CI)]: 0.25 [0.18–0.36]). Additional adjustments for past medical history and laboratory results rarely affected these results. Similarly, in the COVID‐19‐related mortality analysis with 228 731 patients, including 216 781 vaccinated and 11 950 unvaccinated at the end of 2021, COVID‐19‐related mortality risk was significantly lower in the vaccinated group in August, September, October and November (aOR [95% CI]: August, 0.32 [0.12–0.84], September, 0.04 [0.01–0.11]; October, 0.10 [0.01–0.81]; November, 0.05 [0.00–0.79]).
Conclusion
In Japanese patients undergoing haemodialysis, the first or second COVID‐19 vaccine dose was significantly associated with decreased COVID‐19 infection and mortality rates, suggesting its effectiveness in this population. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Endocrinology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
- Department of Health Services Research, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
- Division of Nephrology, Shimoochiai Clinic, Tokyo, Japan.
- Department of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
ORCID-Profile: Yuka Sugawara, Masao Iwagami, Toyohiro Hashiba, Masaomi Nangaku
Förderung
- Ministry of Health, Labour and Welfare
Zitieren
APA
Sugawara, Y., Iwagami, M., Kikuchi, K., Hashiba, T., Yabushita, S., Ryuzaki, M., & Nangaku, M. (2024). Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry. Nephrology. https://doi.org/10.1111/nep.14366
Vancouver
Sugawara Y, Iwagami M, Kikuchi K, Hashiba T, Yabushita S, Ryuzaki M, et al. Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry. Nephrology. 2024. doi:10.1111/nep.14366
BibTeX
@article{Sugawara2024,
author = {Sugawara, Yuka and Iwagami, Masao and Kikuchi, Kan and Hashiba, Toyohiro and Yabushita, Sayaka and Ryuzaki, Munekazu and Nangaku, Masaomi},
title = {Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry},
journal = {Nephrology},
year = {2024},
doi = {10.1111/nep.14366}
}
EUVIMED